Product Description
CDX-1307 is an experimental vaccine that is designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-_). hCG-_ is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. In this study, it is hoped that administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01094496)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Celldex
Company Location: HAMPTON NJ 08827
Company CEO: Anthony S. Marucci
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bladder Cancer
Phase 1: Pancreatic Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Bladder Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CDX-1307-01 | P1 |
Completed |
Pancreatic Cancer|Colorectal Cancer|Ovarian Cancer|Breast Cancer|Bladder Cancer |
2010-05-01 |
2019-03-18 |
||
| CDX1307-02 | P1 |
Completed |
Pancreatic Cancer|Bladder Cancer|Ovarian Cancer|Colorectal Cancer|Breast Cancer |
2009-05-01 |
2019-03-18 |
Treatments |
|
| The "N-ABLE" Study | P2 |
Terminated |
Bladder Cancer |
2011-07-01 |
2020-02-15 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|